PROMO.ST
Promore Pharma AB (publ) [PROMO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PROMO.ST Stock Summary
In the News
PROMO.ST Financial details
Company Rating
Neutral
Market Cap
293.55M
Income
-21.5M
Revenue
259K
Book val./share
0.03
Cash/share
0.06
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
24 Feb 2022
P/E
-0.31
Forward P/E
-
PEG
0.08
P/S
31.1
P/B
3.76
P/C
1.83
P/FCF
-0.32
Quick Ratio
1.66
Current Ratio
2.05
Debt / Equity
0.41
LT Debt / Equity
0.41
-
-
EPS (TTM)
-0.36
EPS next Y
-
EPS next Q
-
EPS this Y
-22.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-22.56%
Revenue last 5Y
-47.35%
Revenue Q/Q
-
EPS Q/Q
4.38%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-446%
ROE
-333%
ROC
-8.68%
Gross Margin
-5170%
Oper. Margin
-9539%
Profit Margin
-9556%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.045-1.995
52W High
-
52W Low
-
RSI
38
Rel Volume
0.54
Avg Volume
2.06M
Volume
1.12M
Perf Week
-99.47%
Perf Month
1.38%
Perf Quarter
-
Perf Half Y
54.49%
-
-
-
-
Beta
1.515
-
-
Volatility
6.26%, 18.08%
Prev Close
-99.22%
Price
0.11
Change
-99.33%
PROMO.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.12 | 0.18 | 0 | 0.01 | 0 | |
| Net income per share | -1.58 | -1.32 | -0.82 | -0.57 | -0.44 | |
| Operating cash flow per share | -1.58 | -0.85 | -1.03 | -0.52 | -0.45 | |
| Free cash flow per share | -1.58 | -0.85 | -1.03 | -0.52 | -0.45 | |
| Cash per share | 1.5 | 2.79 | 0.67 | 0.95 | 0.29 | |
| Book value per share | 1.62 | 2.4 | 0.63 | 0.85 | 0.23 | |
| Tangible book value per share | 1.53 | 2.38 | 0.63 | 0.85 | 0.23 | |
| Share holders equity per share | 1.62 | 2.4 | 0.63 | 0.85 | 0.23 | |
| Interest debt per share | 0.04 | 0.04 | 0.02 | 0.02 | 0.01 | |
| Market cap | 238.43M | 79.88M | 94.78M | 74.88M | 48.81M | |
| Enterprise value | 208.26M | 20.05M | 71.25M | 30.28M | 31.72M | |
| P/E ratio | -7.34 | -2.79 | -3.16 | -2.78 | -1.83 | |
| Price to sales ratio | 97.45 | 20.34 | 31.59K | 179.57 | 493.07 | |
| POCF ratio | -7.33 | -4.33 | -2.53 | -3.02 | -1.79 | |
| PFCF ratio | -7.33 | -4.33 | -2.53 | -3.02 | -1.79 | |
| P/B Ratio | 7.17 | 1.53 | 4.16 | 1.84 | 3.49 | |
| PTB ratio | 7.17 | 1.53 | 4.16 | 1.84 | 3.49 | |
| EV to sales | 85.12 | 5.11 | 23.75K | 72.61 | 320.4 | |
| Enterprise value over EBITDA | -6.62 | -0.72 | -2.55 | -1.13 | -1.19 | |
| EV to operating cash flow | -6.4 | -1.09 | -1.9 | -1.22 | -1.16 | |
| EV to free cash flow | -6.4 | -1.09 | -1.9 | -1.22 | -1.16 | |
| Earnings yield | -0.14 | -0.36 | -0.32 | -0.36 | -0.55 | |
| Free cash flow yield | -0.14 | -0.23 | -0.4 | -0.33 | -0.56 | |
| Debt to equity | 0.02 | 0.01 | 0.03 | 0.02 | 0.05 | |
| Debt to assets | 0.02 | 0.01 | 0.03 | 0.02 | 0.03 | |
| Net debt to EBITDA | 0.96 | 2.15 | 0.84 | 1.67 | 0.64 | |
| Current ratio | 9.82 | 4.23 | 9.64 | 8.36 | 3.33 | |
| Interest coverage | -617.06 | -303.36 | -2.64K | -156.36 | -1.66K | |
| Income quality | 1 | 0.64 | 1.27 | 0.93 | 1.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.36 | 1.83 | 2K | 17.05 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.05 | 0.01 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.59 | 8.45 | 3.4 | 3.29 | 1.51 | |
| ROIC | -0.95 | -0.55 | -1.26 | -0.65 | 0 | |
| Return on tangible assets | -0.91 | -0.42 | -1.14 | -0.57 | -1.27 | |
| Graham Net | 1.32 | 2.13 | 0.57 | 0.82 | 0.18 | |
| Working capital | 29.61M | 49.86M | 22.54M | 41.56M | 14.7M | |
| Tangible asset value | 31.42M | 51.59M | 22.79M | 40.61M | 13.99M | |
| Net current asset value | 28.61M | 48.78M | 21.72M | 40.61M | 13.99M | |
| Invested capital | 0.02 | 0.01 | 0.03 | 0.02 | 0.05 | |
| Average receivables | 798.6K | 1.78M | 1.43M | 164K | 164K | |
| Average payables | 2.36M | 6.77M | 6.62M | 2.51M | 4.36M | |
| Average inventory | 0 | 126.5 | 126.5 | 0 | 0 | |
| Days sales outstanding | 104.06 | 265.49 | 0 | 287.1 | 0 | |
| Days payables outstanding | 19.56 | 219.82 | 20.51 | 95.4 | 108.1 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.51 | 1.37 | 0 | 1.27 | 0 | |
| Payables turnover | 18.66 | 1.66 | 17.8 | 3.83 | 3.38 | |
| Inventory turnover | 0 | 80.23K | 0 | 0 | 0 | |
| ROE | -0.98 | -0.55 | -1.31 | -0.66 | -1.9 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.09 | -0.11 | -0.12 | -0.06 | -0.06 | |
| Operating cash flow per share | -0.1 | -0.09 | -0.14 | -0.07 | -0.06 | |
| Free cash flow per share | -0.1 | -0.09 | -0.14 | -0.07 | -0.06 | |
| Cash per share | 0.39 | 0.29 | 0.15 | 0.09 | 0.06 | |
| Book value per share | 0.34 | 0.23 | 0.11 | 0.05 | 0.03 | |
| Tangible book value per share | 0.34 | 0.23 | 0.11 | 0.05 | 0.03 | |
| Share holders equity per share | 0.34 | 0.23 | 0.11 | 0.05 | 0.03 | |
| Interest debt per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Market cap | 65.87M | 48.81M | 84.09M | 8.89M | 6.13M | |
| Enterprise value | 43.04M | 31.72M | 75.44M | 4.43M | 2.96M | |
| P/E ratio | -3.08 | -1.8 | -2.97 | -0.59 | -0.39 | |
| Price to sales ratio | 6.59K | 493.07 | 2.47K | 70.59 | 0 | |
| POCF ratio | -10.82 | -8.51 | -9.96 | -2.12 | -1.62 | |
| PFCF ratio | -10.82 | -8.51 | -9.96 | -2.12 | -1.62 | |
| P/B Ratio | 3.17 | 3.49 | 12.18 | 2.81 | 3.48 | |
| PTB ratio | 3.17 | 3.49 | 12.18 | 2.81 | 3.48 | |
| EV to sales | 4.3K | 320.4 | 2.22K | 35.18 | 0 | |
| Enterprise value over EBITDA | -8.05 | -4.69 | -10.66 | -1.19 | -0.76 | |
| EV to operating cash flow | -7.07 | -5.53 | -8.93 | -1.06 | -0.78 | |
| EV to free cash flow | -7.07 | -5.53 | -8.93 | -1.06 | -0.78 | |
| Earnings yield | -0.08 | -0.14 | -0.08 | -0.42 | -0.64 | |
| Free cash flow yield | -0.09 | -0.12 | -0.1 | -0.47 | -0.62 | |
| Debt to equity | 0.03 | 0.05 | 0.1 | 0.23 | 0.41 | |
| Debt to assets | 0.03 | 0.03 | 0.07 | 0.12 | 0.15 | |
| Net debt to EBITDA | 4.27 | 2.53 | 1.22 | 1.2 | 0.81 | |
| Current ratio | 7.2 | 3.33 | 3.97 | 2.68 | 2.05 | |
| Interest coverage | 1.34K | -1.35K | -1.77K | 0 | 0 | |
| Income quality | 1.14 | 0.85 | 1.19 | 1.12 | 0.97 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.82 | 0.76 | 0.55 | 0.27 | 0.2 | |
| ROIC | -0.25 | -0.46 | -0.93 | 0 | -1.57 | |
| Return on tangible assets | -0.21 | -0.32 | -0.7 | -0.6 | -0.81 | |
| Graham Net | 0.32 | 0.18 | 0.1 | 0.04 | 0.01 | |
| Working capital | 21.47M | 14.7M | 7.62M | 3.88M | 2.47M | |
| Tangible asset value | 20.75M | 13.99M | 6.9M | 3.17M | 1.76M | |
| Net current asset value | 20.75M | 13.99M | 6.9M | 3.16M | 1.76M | |
| Invested capital | 0.03 | 0.05 | 0.1 | 0.23 | 0.41 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.53M | 3.46M | 3.05M | 1.2M | 998K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 65.72 | 100.78 | 25.05 | 68.47 | 64.1 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.37 | 0.89 | 3.59 | 1.31 | 1.4 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.26 | -0.48 | -1.03 | -1.18 | -2.22 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
PROMO.ST Frequently Asked Questions
What is Promore Pharma AB (publ) stock symbol ?
Promore Pharma AB (publ) is a SE stock and trading under the symbol PROMO.ST
What is Promore Pharma AB (publ) stock quote today ?
Promore Pharma AB (publ) stock price is $0.11 today.
Is Promore Pharma AB (publ) stock public?
Yes, Promore Pharma AB (publ) is a publicly traded company.
Company Profile
- Volume Average 2.06M
- Market Capitalization 293.55M
- Employee 1
- CEO Dr. Jonas Ekblom Ph.D.
- Headquarters Solna,SE
- IPO Date 2017-07-06
-
Website
https://www.promorepharma.com 
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.
